Semaglutide Dosage Protocol: A Start-to-Finish Research Guide

Semaglutide is the most clinically studied peptide of the GLP-1 class. The STEP trial series involving over 4,000 participants gives us precise data on expected outcomes, side effect timing, and optimal titration. Here's how to follow the evidence-based protocol correctly.

The Full Titration Schedule

• Weeks 1–4: 0.25mg once weekly (initiation dose)
• Weeks 5–8: 0.5mg once weekly
• Weeks 9–12: 1mg once weekly
• Weeks 13–16: 1.7mg once weekly (optional escalation)
• Weeks 17+: 2.4mg once weekly (full research dose)

The 4-week intervals are not arbitrary — they match the time needed for GLP-1 receptor adaptation to occur. Rushing the titration is the single most common cause of severe nausea and early discontinuation.

Nausea Management

Nausea affects 40–50% of subjects at some point, predominantly during dose escalation weeks. Strategies that work:

• Inject at night before sleep — if nausea occurs, you sleep through it
• Eat smaller portions. Semaglutide dramatically slows gastric emptying — large meals will cause nausea
• Avoid greasy, fatty, spicy food in the first 48 hours after injection
• Ginger tea or ginger supplements reduce nausea for many
• If nausea is severe: hold at the current dose for an extra 4 weeks before escalating

What to Expect at Each Phase

Weeks 1–4 (0.25mg): Mild appetite reduction. Some subjects notice reduced cravings for processed food. GI adaptation begins. Weight loss typically 1–2kg.

Weeks 5–8 (0.5mg): Appetite suppression becomes significant. Portion sizes decrease naturally. Weight loss accelerates — 0.5–1kg/week common. Nausea most common here.

Weeks 9–16 (1mg): Strong appetite suppression. Food noise (constant thoughts about food) significantly reduced for most subjects. Weight loss continues.

Weeks 17+ (2.4mg): Maximum research dose. STEP 1 data shows 14.9% body weight loss at this dose by week 68.

Plateaus

Weight loss typically slows or pauses at weeks 6–8 and again around weeks 14–16. This is normal metabolic adaptation. Maintaining the dose rather than escalating prematurely during plateaus allows the body to recalibrate. Adding short-term protein fasting (36-hour protein-sparing modified fast) during plateaus can break them without dose escalation.

Discontinuation

Weight regain after stopping semaglutide is documented — approximately 60% of weight lost is regained within 1 year off the drug in clinical trials. Options: long-term maintenance dosing (0.5–1mg weekly), transition to tirzepatide for continued loss, or careful caloric management with resistance training. Abrupt discontinuation does not cause any dangerous withdrawal — appetite simply returns to baseline within 2–4 weeks.

Protein Intake Is Non-Negotiable

At 1mg+ semaglutide, appetite suppression can reduce total intake dramatically — sometimes to 800–1,200 kcal/day. At this intake level, lean mass loss is significant without targeted protein prioritization. Target minimum 120g protein daily regardless of total calorie intake.